Natera (NTRA) Financials: Revenue & Earnings

NTRA$310.67-53.09 -14.59%

$44.78B

Market Cap

—

P/E

—

Forward P/E

45

Score

AI Analysis

Snapshot

Natera is a mixed profile at 45/100 — Value 40, Growth 66, Quality 29. Under the hood: revenue compounding ~42% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

40
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

66
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

29
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Natera, Inc. (NTRA) last printed $310.67. Equity value is $44.78B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$217.07M$210.94M$257.65M$302.33M$391M$625.49M$820.22M$1.08B$1.7B$2.31B

About

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Natera (NTRA) Financials: Revenue & Earnings

NTRA price $310.67 -53.09 -14.59%

Ticker
NTRA
Price
$310.67
Change
-53.09 -14.59%
Market cap ?
$44.78B
Dividend yield ?
0.00%
Beta ?
1.53
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Stocklytics score
45
Value
40
Quality
29
Growth
66

Stocklytics score rationale: value 40, quality 29, growth 66.

AI Score 30. Natera, Inc. has a high price of $378.92 with a market cap of $54.6 billion, but it shows significant financial distress with a negative net profit margin of -0.071 and a price-to-earnings ratio of -278.6

Insights · Forecast · Financials · Learn

Stocklytics home · Screener